Amneal Pharmaceuticals, Inc. Operating Income Loss

• Amneal Pharmaceuticals, Inc. showed an increase of +58.1% in Operating Income Loss from 2024 to 2025.
• This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Amneal Pharmaceuticals, Inc.'s Operating Income Loss has grown by 38.3%.
• Historical annual values: Fiscal year 2025: $394.10 million | Fiscal year 2024: $249.33 million | Fiscal year 2023: $204.37 million | Fiscal year 2022: -$94.93 million | Fiscal year 2021: $152.72 million | Fiscal year 2020: $91.16 million | Fiscal year 2019: -$248.68 million | Fiscal year 2018: -$19.67 million | Fiscal year 2017: $245.10 million | Fiscal year 2016: $284.88 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026